Eng. Mohamed Mubarak Al Mazrouei, Chairman of the Board of Directors of National Medical Solutions LLC (NMS), announced today that all activities are in progress on the building and setting up of the new pharmaceutical factory in Abu Dhabi.
“The factory will be built according to the highest international standards and will occupy 26,000 square meters in an area with easy access to all major infrastructure of the Capital. The trial operation is scheduled to start during the first quarter of 2012” Al Mazrouei said.
Al Mazrouei revealed that the factory’s production capacity will meet the growing demand for intravenous medical solutions and drug products in general within the GCC, Middle East and North Africa.
“The factory’s designs have taken into consideration the future expansion in the production capacity and the ability to add more production lines” he added. Also, he assured that the company’s Board of Directors will always seek to achieve a leading position that aims to serve the health care sector in general, alongside all other economical sectors associated with the pharmaceutical industry.
In this context, an agreement was signed with Foster Wheeler, one of the world’s leading companies with 115 years of distinguished experience in pharmaceutical plants, to ensure that NMS factory meets the highest quality standards in the pharmaceutical industry both locally and globally and qualifies to be accredited (among all local, regional and international pharmaceutical factories) for the relevant standards.
The agreement was signed by Mr. Ibrahim Sleiman, CEO of NMS and Chairman of the Board of Directors of TS Investment (TSI) Ltd), and Mr. Francisco Dendo, Director of the Pharmaceutical Industries representing Foster Wheeler.
Al Mazrouei, also pointed out that the factory will operate with local national efforts to be one of the main factors enhancing the industrial sector’s growth within Abu Dhabi, in line with Abu Dhabi economical vision 2030, which aims to achieve social welfare and sustainable development within all sectors, especially the health sector, to reach self-sufficiency in most strategic pharmaceutical indispensable products.
WAM